• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Oncology

ChatGPT accurately selects imaging modality for breast cancer screening and pain assessment

byKiera Liblik
June 22, 2023
in Oncology
Reading Time: 3 mins read
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Share on FacebookShare on Twitter

1. In this clinical decision support study, the performance of the Chat Generative Pre-training Transformer (ChatGPT) in recommending appropriate imaging for breast pain and cancer patient scenarios was assessed according to the American College of Radiology (ACR) Appropriateness Criteria.

2. ChatGPT versions 3.5 and 4 were correct 88.9% and 98.4% of the time for ‘select all that apply’ (SATA) questions on breast cancer screening cases compared to 58.3% and 77.7% for questions on breast pain cases.

Evidence Rating Level: 1 (Excellent)

Study Rundown: ChatGPT is a transformer-based language model which leverages human input and supervised learning to generate text responses to inputs. Emerging literature suggests that ChatGPT may aid in clinical decision support, with the capacity to be trained to assess patient data in the context of previous medical literature. The present study presented ChatGPT versions 3.5 and 4 with prompts containing information on patients with breast pain or who were being screened for breast cancer. Prompts were either written as open-ended (OE) questions or in a SATA format on image modality selection for the cases. Answers were assessed according to the ACR Appropriateness Criteria for breast pain and cancer screening. ChatGPT performed with moderate accuracy for both breast pain and breast cancer screening, with a higher percentage of correct answers for breast cancer screening questions. Additionally, it performed better on SATA than OE prompts with ChatGPT 4 achieving higher scores overall than ChatGPT 3.5. As data on the development of ChatGPT is private, a major limitation of this study is that it is not known if it has been previously exposed to ACR criteria. This impairs the assessment of ChatGPT’s decision-making. Overall, the study demonstrates that ChatGPT is able to aid in radiologic decision-making with moderate accuracy in the context of breast pain and cancer screening.

Click to read the study in the Journal of the American College of Radiology

Relevant Reading: Large language model (ChatGPT) as a support tool for breast tumor board

RELATED REPORTS

Historical redlining associated with lower breast cancer screening across urban neighborhoods

FDA-cleared AI devices rarely have patient outcome data

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

In-Depth [clinical decision support study]: This clinical decision support study assessed ChatGPT’s accuracy in selecting appropriate imaging for breast cancer screening and breast pain patient prompts. ChatGPT versions 3.5 and 5 were used, with answers being scored against ACR Appropriateness Criteria. For each prompt used, three separate team members put the information into ChatGPT, resulting in three outputs per version of ChatGPT per prompt. The answers provided by ChatGPT were then scored independently by two team members, between which there were no disagreements regarding any answers. OE outputs were scored out of two, while SATA outputs were scored out of 100%. In terms of SATA prompts, ChatGPT scored 88.9% (version 3.5) and 98.4% (version 4) for breast cancer screening questions as well as 1.83 for OE prompts (version 3.5 and 4). For breast pain imaging selection, ChatGPT versions 3.5 and 4 had lower scores SATA (58.3% and 77.7%, respectively) and OE scores (1.125 and 1.666, respectively). Notably, ChatGPT was more likely to provide paragraph-form reasoning for the outputs provided on OE prompts. Though the accuracy of ChatGPT version 4 did not vary with the severity of cases presented, version 3.5 performed better on breast cancer screening cases with low severity and breast pain cases with higher severity. ChatGPT version 4 also differed in that it was able to identify a scenario where no imaging was needed. In summary, the present study provides critical information on the performance of ChatGPT versions 3.5 and 4 in recommending imaging modalities for patients being screened for breast cancer and assessed for breast pain.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancerbreast cancer screeningbreast imagingchatGPTmachine learning
Previous Post

Wellness Check: Exercise

Next Post

Ultrasonography noninferior to radiography for guiding pediatric fracture management

RelatedReports

Oncology

Historical redlining associated with lower breast cancer screening across urban neighborhoods

September 13, 2026
Public Health

FDA-cleared AI devices rarely have patient outcome data

September 10, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026
Next Post
Adolescent mothers in protective care more likely to have their children placed in care

Ultrasonography noninferior to radiography for guiding pediatric fracture management

Pediatric palliative care outcome measures often miss quality of life

Treatment of gestational diabetes before 20 weeks' gestation improves neonatal outcomes

Being overweight and obese associated with increased incidence of chronic kidney disease

Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The rate of urethrocutaneous fistula following caudal and penile blocks for hypospadias repair may be similar
  • Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma
  • Deep learning model improved cancer recurrence prediction for pediatric glioma using serial imaging
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.